share_log

Novavax | 10-Q: Q3 2024 Earnings Report

Novavax | 10-Q: Q3 2024 Earnings Report

諾瓦瓦克斯醫藥 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/13 05:14

Moomoo AI 已提取核心訊息

Novavax reported Q3 2024 revenue of $84.5 million, down from $187.0 million in Q3 2023, with product sales rising to $38.2 million from $2.2 million. The quarter saw licensing and royalty revenue of $46.3 million, including $32.7 million from the Sanofi collaboration. Net loss narrowed to $121.3 million or $0.76 per share, compared to $130.8 million or $1.26 per share last year.The company strengthened its financial position through a strategic partnership with Sanofi, receiving a $500 million upfront payment and potential milestone payments up to $700 million. Operating expenses decreased 30% year-over-year to $218.5 million, reflecting cost reduction initiatives. Cash and investments totaled $924.5 million as of September 30, 2024.Looking ahead, Novavax is advancing its COVID-19 vaccine program with recent authorizations in the US and EU for its 2024-2025 updated vaccine. The company continues to evolve its operating model focusing on the Sanofi partnership, pipeline development including COVID-Influenza combination vaccine, and leveraging its Matrix-M adjuvant technology platform while implementing further cost reductions.
Novavax reported Q3 2024 revenue of $84.5 million, down from $187.0 million in Q3 2023, with product sales rising to $38.2 million from $2.2 million. The quarter saw licensing and royalty revenue of $46.3 million, including $32.7 million from the Sanofi collaboration. Net loss narrowed to $121.3 million or $0.76 per share, compared to $130.8 million or $1.26 per share last year.The company strengthened its financial position through a strategic partnership with Sanofi, receiving a $500 million upfront payment and potential milestone payments up to $700 million. Operating expenses decreased 30% year-over-year to $218.5 million, reflecting cost reduction initiatives. Cash and investments totaled $924.5 million as of September 30, 2024.Looking ahead, Novavax is advancing its COVID-19 vaccine program with recent authorizations in the US and EU for its 2024-2025 updated vaccine. The company continues to evolve its operating model focusing on the Sanofi partnership, pipeline development including COVID-Influenza combination vaccine, and leveraging its Matrix-M adjuvant technology platform while implementing further cost reductions.
諾瓦瓦克斯醫藥報告2024年第三季度營業收入爲8450萬美元，較2023年第三季度的18700萬美元下降，產品銷售從220萬美元上升至3820萬美元。該季度許可和特許權使用費收入爲4630萬美元，其中3270萬美元來自賽諾菲安萬特的合作。淨虧損縮窄至12130萬美元或每股0.76美元，去年爲13080萬美元或每股1.26美元。公司通過與賽諾菲安萬特的戰略合作加強了財務狀況，獲得了50000萬美元的預付款以及最高可達70000萬美元的潛在里程碑付款。營業費用同比減少30%，降至21850萬美元，反映了成本削減舉措。截至2024年9月30日，現金和投資總額爲92450萬美元。展望未來，諾瓦瓦克斯醫...展開全部
諾瓦瓦克斯醫藥報告2024年第三季度營業收入爲8450萬美元，較2023年第三季度的18700萬美元下降，產品銷售從220萬美元上升至3820萬美元。該季度許可和特許權使用費收入爲4630萬美元，其中3270萬美元來自賽諾菲安萬特的合作。淨虧損縮窄至12130萬美元或每股0.76美元，去年爲13080萬美元或每股1.26美元。公司通過與賽諾菲安萬特的戰略合作加強了財務狀況，獲得了50000萬美元的預付款以及最高可達70000萬美元的潛在里程碑付款。營業費用同比減少30%，降至21850萬美元，反映了成本削減舉措。截至2024年9月30日，現金和投資總額爲92450萬美元。展望未來，諾瓦瓦克斯醫藥正在推進其COVID-19生物-疫苗項目，最近在美國和歐盟獲得了2024-2025年更新生物-疫苗的授權。公司持續優化其運營模式，專注於與賽諾菲安萬特的合作、管道開發（包括COVID-流感組合生物-疫苗）以及利用其Matrix-m佐劑技術平台，同時實施進一步的成本削減。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。